An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients

Padma‐Nathan, Harin; Yeager, James L.

doi:10.1016/j.urology.2006.02.027

Cited by 55 publications

(64 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A pilot study (in summary form) involved 30 patients who applied the cream 5-20 min before intercourse. 87 There was a significant synergistic effect observed with the cream containing 0.5% dyclonine/ 0.4% alprostadil compared with creams containing 1% dyclonine alone or 0.4% alprostadil alone (P,0.05). The mean IELTs after dosing were 2.34 and 4.08 min in the placebo and dyclonine/alprostadil combination groups, respectively (P,0.05).…”

Section: On-demand Therapy Of Ssrismentioning

confidence: 89%

Current therapeutic strategies for premature ejaculation and future perspectives

Xin¹,

Zhu²,

Yuan³

et al. 2011

Asian J Androl

View full text Add to dashboard Cite

Premature ejaculation (PE) is a common sexual disorder in men that is mediated by disturbances in the peripheral and central nervous systems. Although all pharmaceutical treatments for PE are currently used 'off-label', some novel oral agents and some newer methods of drug administration now provide important relief to PE patients. However, the aetiology of this condition has still not been unified, primarily because of the lack of a standard animal model for basic research and the absence of a widely accepted definition and assessment tool for evidence-based clinical studies in patients with PE. In this review, we focus on the current therapeutic strategies and future treatment perspectives for PE. Ejaculation is a tightly coordinated activity with different ejaculatory organs and a spinal reflex initiated by genital and/or brain stimulation through the peripheral sensory receptors and regions, afferent pathways, the central nervous system ejaculatory centre of the brain (namely, sensory and motor areas located in the para-ventricular nucleus of the hypothalamus and the medial preoptic area). The spinal ejaculatory centre, located at the T 12 -L 1-2 spinal cord level (paragigantocellular), and its efferent pathway modulate the function of the ejaculatory organs. Ejaculation is also mediated by a complex interaction of central serotonergic and dopaminergic neurons with the secondary involvement of cholinergic, adrenergic, oxytocinergic and GABAergic neurons.Ejaculation consists of two main phases, the emission phase and the expulsion phase. The emissions include seminal fluid and secretions of the prostate and bulbourethral glands. In this phase, the contraction of accessory ejaculatory organs induces the accumulation of semen in the posterior urethra. Expansion of the posterior urethra creates a feeling of emission and sensory information that is transmitted to the spine via dorsal nerve sensory pathway and along the spinal cord up to the brain ejaculatory centre during the sexual arousal phase. The expulsion phase consists of the highly regular rhythmic contraction of striated muscles and the relaxation of smooth muscles in the ejaculatory ducts. The ejaculated semen can be divided into a number of components by serial biochemical analysis. 1 These include secretions from the seminal vesicles, prostate and bulbourethral (Cowper's) glands and spermatozoa.

show abstract

Section: On-demand Therapy Of Ssrismentioning

confidence: 89%

Current therapeutic strategies for premature ejaculation and future perspectives

Xin¹,

Zhu²,

Yuan³

et al. 2011

Asian J Androl

View full text Add to dashboard Cite

show abstract

“…11 Topical alprostadil cream was found to improve several secondary efficacy variables relating to ED, compared with placebo, including the other IIEF domain scores (orgasmic function, intercourse satisfaction, and overall satisfaction), PSAE, and GAQ. Adverse effects were mainly related to application site erythema and burning with associated meatal or glans pain but these were generally tolerated.…”

Section: Clinical Experiencementioning

confidence: 95%

New treatments for erectile dysfunction

Seewoodhary

Wong

2015

Br J Diabetes

View full text Add to dashboard Cite

Erectile dysfunction (ED) is common in men with diabetes and is associated with microvascular disease, maladaptation to chronic illness, poor quality of life, and increased levels of diabetes-specific health distress. Traditionally, most diabetologists were poor at asking about ED and patients themselves are not always forthcoming with information, given the embarrassing nature of the disease. However, times are changing and the inclusion of screening for ED in Quality and Outcomes Framework and current general practice templates emphasises its current importance. Licensed treatments have been limited in their application towards the provision of symptomatic relief and are offset by adverse effects, intolerance, limited effectiveness and contraindications in the presence of co-existent cardiovascular disease. This review critically considers the utility of novel treatments for ED in diabetes that have been developed to overcome these barriers. Br J Diabetes Vasc Dis 2015;15:50-55

show abstract

“…in men with diabetes, metabolic syndrome, after radical prostatectomy and after unsuccessful treatment with sildenafil [38]. Moreover, alprostadil in cream was also effective and safe in patients with hypertension, taking nitrates or alpha inhibitors [38]. In general, in the phase 2 and 3 trials, alprostadil in cream administered into the external urethral meatus resulted in an adequate erection in 74-83% of patients [38,41].…”

Section: Alprostadil In Creammentioning

confidence: 98%

“…Phase 2 and 3 trials proved the effectiveness of the preparation when it was used in cases that are difficult to treat, i.e. in men with diabetes, metabolic syndrome, after radical prostatectomy and after unsuccessful treatment with sildenafil [38]. Moreover, alprostadil in cream was also effective and safe in patients with hypertension, taking nitrates or alpha inhibitors [38].…”

Section: Alprostadil In Creammentioning

confidence: 99%

“…The vast majority (97%) of side effects observed in studies was characterised by low intensity and short duration not exceeding 60 minutes [34][35][36][37][38][39][40]. Almost all the side effects limited to the site of administration of the cream and they mostly included: burning of the penis (23%), redness of the glans (11.3%), and balanitis (4.6%) [38]. About 2% of sexual female partners of men using alprostadil in cream without a condom reported mild vaginal burning that disappeared within an hour.…”

Section: Alprostadil In Creammentioning

confidence: 99%

See 1 more Smart Citation

Alprostadil in cream — a new option of treating erectile dysfunctions in diabetic patients

Życzkowski

Nabrdalik

Kwiendacz

et al. 2017

Clinical Diabetology

View full text Add to dashboard Cite

show abstract

An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients

Cited by 55 publications

References 15 publications

Current therapeutic strategies for premature ejaculation and future perspectives

Current therapeutic strategies for premature ejaculation and future perspectives

New treatments for erectile dysfunction

Alprostadil in cream — a new option of treating erectile dysfunctions in diabetic patients

Contact Info

Product

Resources

About